In Journal of Antimicrobial Chemotherapy Mike Ruth, Jakko van Ingen and colleagues showed, using the hollow fiber pharmacodynamic model, that minocycline may be useful to treat pulmonary diseases caused by Mycobacterium avium complex bacteria. This opportunistic infection is increasing in prevalence and outcomes of current treatment regimens are very poor. Minocycline is an old, safe and well tolerated antibiotic that may improve treatment outcomes.Abstract
Our aim was to identify the pharmacokinetic/pharmacodynamic parameters of minocycline in the hollow-fibre system (HFS) model of pulmonary Mycobacterium avium complex (MAC) and to identify the optimal clinical dose.
Minocycline MICs for 55 MAC clinical isolates from the Netherlands were determined. We also co-incubated primary isolated macrophages infected with MAC with minocycline. Next, we performed a 28 day HFS-MAC model dose-response study in which we mimicked pulmonary concentration-time profiles achieved in patients. The HFS-MAC model was sampled at intervals to determine the minocycline pharmacokinetics and MAC burden. We identified the AUC0-24/MIC ratios associated with 1.0 log10 cfu/mL kill below day 0 (stasis), defined as a bactericidal effect. We then performed 10 000 Monte Carlo experiments to identify the optimal dose for a bactericidal effect in patients.
The MIC for 50% and 90% of cumulative clinical isolates was 8 and 64 mg/L, respectively. Minocycline decreased MAC bacterial burden below stasis in primary isolated macrophages. In the HFS-MAC model, minocycline achieved a microbial kill of 3.6 log10 cfu/mL below stasis. The AUC0-24/MIC exposure associated with a bactericidal effect was 59. Monte Carlo experiments identified a minocycline susceptibility MIC breakpoint of 16 mg/L. At this proposed breakpoint, the clinical dose of 200 mg/day achieved the bactericidal effect exposure target in ∼50% of patients, while 400 mg/day achieved this in 73.6% of patients, in Monte Carlo experiments.
Minocycline at a dose of 400 mg/day is expected to be bactericidal. We propose a clinical trial for validation.
Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.
Ruth MM, Magombedze G, Gumbo T, Bendet P, Sangen JJN, Zweijpfenning S, Hoefsloot W, Pennings L, Koeken VACM, Wertheim HFL, Lee PS, van Ingen J, Deshpande D.
Mike Ruth and Jakko van Ingen are members of theme Infectious disease and global health.
Related news items
ERC Consolidator Grant for Bousema and Sechopoulos12 December 2019
Teun Bousema and Ioannis Sechopoulos are to receive an ERC Consolidator Grant of around two million euros each. This European research subsidy will enable them to carry out research for the next five years.read more
New insights into the initiation of T cell responses in the spleen11 December 2019
Carl Figdor and colleagues, theme Cancer development and immune defense, provide insights into the initiation of T cell responses in the spleen and their consequences for T cell differentiation. They have published their results in Proceedings of the National Academy of Sciences USA.read more
Two teams of RIMLS-FNWI participate in Alpe d'HuZes10 December 2019
Sixteen employees of the research institute RIMLS-FNWI have taken on the challenge to run, bike or hike up the mountain Alpe d’Huez as many times as possible 4 June 2020, to raise as much money as possible for cancer research.read more
Dietrich-Knorr Prize for Hedi Claahsen-van der Grinten10 December 2019
Hedi Claahsen-van der Grinten, theme Vascular damage, received the Dietrich-Knorr prize 2019 for the best published paper in the field of adrenal research, for her publication in the Journal of Clinical endocrinology & Metabolism.read more
FIGHT-CNNM2 grant for Joost Hoenderop9 December 2019
Joost Hoenderop, theme Renal disorders, received an European Joint Programme Rare Diseases grant for his project, entitled 'Improving diagnostics and grasping the disease mechanisms of rare Hypomagnesemia in patients with CNNM2 mutations'.read more
Response to treatment of Autoimmune Hepatitis6 December 2019
In a study of patients with Autoimmune Hepatitis and published in Clinial Gastroenterology and Hepatology, Simon Pape and Joost Drenth, found that a rapid response to treatment, based on level of AST after 8 weeks, associates with normalization of transaminase levels in the following year.read more